UK 383367

BMP-1/PCP inhibitor,potent and selective CAS# 348622-88-8

UK 383367

Catalog No. BCC2308----Order now to get a substantial discount!

Product Name & Size Price Stock
UK 383367: 5mg $23 In Stock
UK 383367: 10mg Please Inquire In Stock
UK 383367: 20mg Please Inquire Please Inquire
UK 383367: 50mg Please Inquire Please Inquire
UK 383367: 100mg Please Inquire Please Inquire
UK 383367: 200mg Please Inquire Please Inquire
UK 383367: 500mg Please Inquire Please Inquire
UK 383367: 1000mg Please Inquire Please Inquire
Related Products
  • Batimastat (BB-94)

    Catalog No.:BCC1223
    CAS No.:130370-60-4
  • GM 6001

    Catalog No.:BCC2119
    CAS No.:142880-36-2
  • Ro 32-3555

    Catalog No.:BCC2377
    CAS No.:190648-49-8
  • PD 166793

    Catalog No.:BCC2376
    CAS No.:199850-67-4
  • CP 471474

    Catalog No.:BCC2373
    CAS No.:210755-45-6
  • ARP 100

    Catalog No.:BCC2370
    CAS No.:704888-90-4

Quality Control of UK 383367

Number of papers citing our products

Chemical structure

UK 383367

3D structure

Chemical Properties of UK 383367

Cas No. 348622-88-8 SDF Download SDF
PubChem ID 9818682 Appearance Powder
Formula C15H24N4O4 M.Wt 324.38
Type of Compound N/A Storage Desiccate at -20°C
Solubility Soluble to 100 mM in DMSO
Chemical Name 5-[(3R)-6-cyclohexyl-1-(hydroxyamino)-1-oxohexan-3-yl]-1,2,4-oxadiazole-3-carboxamide
SMILES C1CCC(CC1)CCCC(CC(=O)NO)C2=NC(=NO2)C(=O)N
Standard InChIKey ARJCBSRIPGJMAD-LLVKDONJSA-N
Standard InChI InChI=1S/C15H24N4O4/c16-13(21)14-17-15(23-19-14)11(9-12(20)18-22)8-4-7-10-5-2-1-3-6-10/h10-11,22H,1-9H2,(H2,16,21)(H,18,20)/t11-/m1/s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of UK 383367

DescriptionPotent and selective inhibitor of BMP-1 (procollagen C-proteinase; PCP) (IC50 = 44 nM). Selective for BMP-1 over MMPs 1, 2, 3, 9 and 14 (IC50 values are >10,000 nM for listed MMPs).

UK 383367 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

UK 383367 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of UK 383367

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 3.0828 mL 15.414 mL 30.828 mL 61.6561 mL 77.0701 mL
5 mM 0.6166 mL 3.0828 mL 6.1656 mL 12.3312 mL 15.414 mL
10 mM 0.3083 mL 1.5414 mL 3.0828 mL 6.1656 mL 7.707 mL
50 mM 0.0617 mL 0.3083 mL 0.6166 mL 1.2331 mL 1.5414 mL
100 mM 0.0308 mL 0.1541 mL 0.3083 mL 0.6166 mL 0.7707 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on UK 383367

UK 383367 is a novel procollagen C-protein (PCP) inhibitor being investigated for the treatment of post-surgical dermal scarring, which potently inhibits the activity of PCP with the value of 50% inhibition concentration IC50 of 44 nM, as well as a selective inhibitor of matrix metalloproteinases (MMPs) with values of IC50 >60,000 nM for MMP-2 and >10,000 nM for MMP-1, MMP-3, MMP-9 and MMP-4. Although the mechanism is not clear yet, UK 383367 also exhibits weak inhibitory effects against phosphodiesterase-4 (PDE-4) enzyme, including PDE-4a, PDE-4b, PDE-4c and PDE-4d, with values of IC50 of 1.8 μM, 1.5 μM, 2.4 μM and 0.9 μM respectively.

Reference

G. A. Allan, J. I. Gedge, A. N. R. Nedderman, S. J. Roffey, H. F. Small and R. Webster. Pharmacokinetics and metabolism of UK-383,367 in rats and dogs: a rationale for long-lived plasma radioactivity. Xenobiotica 2006; 36(5): 399-418

Bailey S, Fish PV, Billotte S, Bordner J, Greiling D, James K, McElroy A, Mills JE, Reed C, Webster R.ff. Succinyl hydroxamates as potent and selective non-peptidic inhibitors of procollagen C-proteinase: design, synthesis, and evaluation as topically applied, dermal anti-scarring agents. Bioorg Med Chem Lett. 2008;18(24):6562-6567

Featured Products
New Products
 

References on UK 383367

Pharmacokinetics and metabolism of UK-383,367 in rats and dogs: a rationale for long-lived plasma radioactivity.[Pubmed:16854779]

Xenobiotica. 2006 May;36(5):399-418.

UK-383,367 (5-{(1R)-4-cyclohexyl-1-[2-(hydroxyamino)-2-oxoethyl]butyl}-1,2,4-oxadiazole-3-ca rboxamide) is a novel procollagen C-proteinase inhibitor evaluated for the treatment of post-surgical dermal scarring. It is extensively metabolized in rat and dog absorption, distribution, metabolism and excretion studies, and a metabolic pathway for UK-383,367 was determined. A long-lived metabolite was identified in dog plasma. Data indicate that this metabolite results from the oxadiazole ring-cleavage-producing oxamic acid, oxamide and oxalic acid. Ion exclusion chromatography was used to identify these polar metabolites, which were unretained on a standard reversed-phase high-performance liquid chromatography system. The oxamide metabolite was identified as the long-lived radioactivity, which was observed in dog plasma.

Succinyl hydroxamates as potent and selective non-peptidic inhibitors of procollagen C-proteinase: design, synthesis, and evaluation as topically applied, dermal anti-scarring agents.[Pubmed:18945617]

Bioorg Med Chem Lett. 2008 Dec 15;18(24):6562-7.

Succinyl hydroxamates 1 and 2 are disclosed as novel series of potent and selective inhibitors of procollagen C-proteinase (PCP) which may have potential as anti-fibrotic agents. Carboxamide 7 demonstrated good PCP inhibition and had excellent selectivity over MMPs involved in wound healing. In addition, 7 was effective in a cell-based model of collagen deposition (fibroplasia model) and was very effective at penetrating human skin in vitro. Compound 7 (UK-383,367) was selected as a candidate for evaluation in clinical studies as a topically applied, dermal anti-scarring agent.

Potent and selective nonpeptidic inhibitors of procollagen C-proteinase.[Pubmed:17591762]

J Med Chem. 2007 Jul 26;50(15):3442-56.

6-Cyclohexyl-N-hydroxy-3-(1,2,4-oxadiazol-5-yl)hexanamides were previously disclosed as inhibitors of procollagen C-proteinase (PCP) culminating in the identification of amide 1. Our objective was to discover a second inhibitor that would have improved affinity for PCP and to optimize properties for transepidermal delivery (TED) to intact skin. Further investigation of this template identified a number of potent PCP inhibitors (IC50 values of 2-6 nM) with improved TED flux. Sulfonamide 56 had excellent PCP enzyme activity when measured with a peptide substrate (Ki 8.7 nM) or with the endogenous substrate procollagen (IC50 3.4 nM) and demonstrates excellent selectivity over MMPs involved in wound healing (>10 000-fold). In the fibroplasia model, 56 inhibited deposition of insoluble collagen by 76 +/- 2% at 10 microM and was very effective at penetrating human skin in vitro with a TED flux of 1.5 microg/cm2/h, which compares favorably with values for agents that are known to penetrate skin well in vivo. Based on this profile, 56 (UK-421,045) was selected as a candidate for further preclinical evaluation as a topically applied, dermal anti-scarring agent.

Description

UK-383367 (UK 383367) is a potent and selective inhibitor of BMP-1 (procollagen C-proteinase) with IC50 of 44 nM; Selective for BMP-1 over MMPs 1, 2, 3, 9 and 14 (IC50 values are >10,000 nM for listed MMPs).

Keywords:

UK 383367,348622-88-8,Natural Products,Procollagen C Proteinase, buy UK 383367 , UK 383367 supplier , purchase UK 383367 , UK 383367 cost , UK 383367 manufacturer , order UK 383367 , high purity UK 383367

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: